High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

Completed

Looking for future studies?

Key information

Conditions

Multiple Myeloma Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

About this study

To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous stem cell rescue in the treatment of multiple myeloma.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- received cytoreduction prior to transplant

adequate organ function Exclusion Criteria:- previous transplant
smoldering MM or benign monoclonal gammopathy

Treatment and study plan

high dose chemotherapy then autologous hematopoietic cell transplant

Procedure

Primary outcomes

Toxicity and efficacy of sequentially administered high dose chemotherapy and autologous hematopoietic cell transplantation

Time frame: Patients will have a daily CBC with platelet count, and chemistries until engraftment, then as indicated clinically. Chest x-rays will be done weekly until engraftment, then as indicated clinically. Patients will be restaged for abnormal proteins (SPIE)

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start: 1994
Primary completion: 2006
Study completion: 2010
First posted: Sep 16, 2005
Registry last updated: Sep 14, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed